MOH — authorised 6 March 2020
- Marketing authorisation holder: RECORDATI RARE
- Status: likely_approved
MOH authorised Isturisa on 6 March 2020
Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.
Yes. MOH authorised it on 6 March 2020.
RECORDATI RARE holds the Israeli marketing authorisation.